Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,207 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID Clear all
Terminated Not applicable Interventional

Long COVID-19 Rehabilitation & Recovery Research Program

NCT05398692
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, COVID-19
Interventions
On Site Exercise Rehabilitation
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 27, 2026, 10:20 PM EDT
Recruiting Phase 2 Interventional

Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS

NCT07189936
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS), SARS CoV 2 Infection, Long COVID19
Interventions
To Measure levels of circulating monocyte/ T cell doublets at Baseline, To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment, To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment, To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA, To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo, To Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA, To Measure Orthostatic Tachycardia after 28 days of Treatment with Placebo
Drug · Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 27, 2026, 10:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults

NCT04785144
View directory record Official record
Conditions
COVID-19, COVID-19 Immunisation
Interventions
mRNA-1273, mRNA-1273.351
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Decatur, Georgia • Cincinnati, Ohio • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 27, 2026, 10:20 PM EDT
Recruiting Not applicable Interventional

Improving the Health and Social Participation of People With Disabilities From Underrepresented Groups Post COVID

NCT05792852
View directory record Official record
Conditions
Disabilities Multiple
Interventions
ENGAGE
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 27, 2026, 10:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina Personnel

NCT04561089
View directory record Official record
Conditions
SARS-CoV-2
Interventions
COVIDSeq Test
Diagnostic Test
Lead sponsor
Illumina, Inc.
Industry
Eligibility
18 Years and older
Enrollment
763 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Foster City, California • Hayward, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 27, 2026, 10:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of the Effectiveness of Moderna COVID-19 Vaccine

NCT05933304
View directory record Official record
Conditions
SARS-CoV-2, COVID-19
Interventions
Not listed
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
6 Months and older
Enrollment
927,004 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 27, 2026, 10:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV

NCT04958889
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), HIV
Interventions
No intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 27, 2026, 10:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Rural Tailored COVID-19 Communication to Promote SARS-CoV-2 Antibody Testing in Saliva

NCT06085547
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
General SARS-CoV-2 Communication, Rural-Targeted SARS-CoV-2 Communication
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 27, 2026, 10:20 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

NCT04750278
View directory record Official record
Conditions
Severe to Critical COVID 19 With Associated ARDS
Interventions
FP-025 100 mg, FP-025 300 mg, Placebo
Drug
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Chula Vista, California • La Mesa, California • Rockville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 27, 2026, 10:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safe and Healthy Schools

NCT05105789
View directory record Official record
Conditions
Sars-CoV-2 Infection, COVID-19
Interventions
BinaxNOW Test, "Lollipop" swab
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 27, 2026, 10:20 PM EDT
Completed No phase listed Observational

Role of OMT in the Management of the Persistent Post-COVID-19 Symptoms

NCT06016543
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
osteopathic manipulative treatment (OMT)
Procedure
Lead sponsor
A.T. Still University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kirksville, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 27, 2026, 10:20 PM EDT
Active, not recruiting No phase listed Observational

NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19

NCT05292274
View directory record Official record
Conditions
COVID-19, SARS CoV 2 Infection
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 27, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

Plasma Therapy of COVID-19 in Severely Ill Patients

NCT04359810
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Convalescent Plasma (anti-SARS-CoV-2 plasma), Non-convalescent Plasma (control plasma)
Biological
Lead sponsor
Max O'Donnell
Other
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 10:20 PM EDT
Completed No phase listed Observational

EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic ( EPISODEPSCOVID )

NCT04445493
View directory record Official record
Conditions
Stroke, Acute, COVID-19
Interventions
MindRhythm Harmony
Device
Lead sponsor
MindRhythm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 27, 2026, 10:20 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

NCT04540185
View directory record Official record
Conditions
Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
Interventions
Biological: oral polio vaccine, Comparable Placebo, NA-831, Comparable Placebo of drug, Combination of oral polio vaccine and NA-831, Comparable Placebo of Oral Polio Vaccine and Placebo of drug
Biological · Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 27, 2026, 10:20 PM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3127804 in Participants With COVID-19

NCT04342897
View directory record Official record
Conditions
COVID-19, Pneumonia
Interventions
LY3127804, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
13
States / cities
Phoenix, Arizona • Tucson, Arizona • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 27, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

Frontline Clinician Psilocybin Study

NCT05163496
View directory record Official record
Conditions
Burnout, Caregiver, Burnout, Professional, COVID-19, Depression, Post Traumatic Stress Disorder, Moral Injury
Interventions
Psilocybin (Usona Institute), Active placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 27, 2026, 10:20 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)

NCT04363450
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, Wuhan Coronavirus, Prophylaxis, Healthcare Worker, Sars-CoV2, Hydroxychloroquine
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
1,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Lafayette, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 27, 2026, 10:20 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Parkinson's Disease and Experiences Throughout the COVID-19 Pandemic

NCT04720118
View directory record Official record
Conditions
Parkinson Disease, Covid19, Satisfaction, Patient, Quality of Life
Interventions
No Intervention
Other
Lead sponsor
Towson University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 27, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)

NCT04402970
View directory record Official record
Conditions
SARS-CoV 2, ARDS
Interventions
Dornase Alfa Inhalation Solution
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 27, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

NCT05329220
View directory record Official record
Conditions
COVID-19 Disease
Interventions
ABNCoV2, Comirnaty
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older
Enrollment
4,205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
44
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 27, 2026, 10:20 PM EDT
Withdrawn Not applicable Interventional

CAPTION AI to Minimize Risk of COVID Exposure

NCT04336774
View directory record Official record
Conditions
COVID-19
Interventions
Caption AI
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 27, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

NCT04375397
View directory record Official record
Conditions
CoronaVirus Induced Disease-2019 (COVID-19)
Interventions
Ibrutinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Stanford, California • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 27, 2026, 10:20 PM EDT
Completed No phase listed Observational

VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease

NCT04587323
View directory record Official record
Conditions
COVID-19 Disease
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 27, 2026, 10:20 PM EDT